A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

September 9, 2017

Study Completion Date

June 4, 2019

Conditions
Prostate Cancer
Interventions
DRUG

Ibrance

DRUG

Bicalutamide

DRUG

Zoladex

DRUG

Lupron Depot

Trial Locations (8)

19107

Thomas Jefferson University, Philadelphia

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

37232

Vanderbilt-Ingram Cancer Center, Nashville

48109

University of Michigan Hospital, Ann Arbor

60611

Northwestern University, Chicago

63110

Washington University in St. Louis, St Louis

84112

Huntsman Cancer Institute, University of Utah, Salt Lake City

91010

City of Hope Cancer Center, Duarte

All Listed Sponsors
collaborator

University of Utah

OTHER

collaborator

Vanderbilt-Ingram Cancer Center

OTHER

collaborator

Johns Hopkins University

OTHER

collaborator

Thomas Jefferson University

OTHER

collaborator

Washington University School of Medicine

OTHER

collaborator

Northwestern University

OTHER

collaborator

City of Hope Comprehensive Cancer Center

OTHER

lead

University of Michigan Rogel Cancer Center

OTHER

NCT02059213 - A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter